Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Indivior PLC
Indivior PLC
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Andelyn Biosciences and Grace Science, LLC partner to manufacture AAV gene therapy
The partnership will seek to maximise programme efficiency, support the ongoing clinical trial and accelerate this critical therapy to patients
Teva UK and Closed Loop Medicine partner to advance personalised medicine development
SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Henkel facilities receive EXCiPACT certificate as suppliers of pharmaceutical excipients
The certification means Henkel meets EXCiPACT’s guidelines for good manufacturing practice (GMP) and good distribution practice (GDP)
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Design & Build
Indivior awards BES £4m design project
The cleanroom construction company has been chosen to create a new production facility for the opioid addiction treatment specialist
Design & Build
Boulting Environmental Services completes Indivior R&D facility
The UK-based cleanroom and lab design and construction company has completed the construction phase of a £13 million project for global pharmaceutical business Indivior, a specialist in the treatment of opioid addiction
Research & Development
New schizophrenia drug may improve patient compliance
RBP-7000, new pipeline novel sustained-release drug by Indivior, showed patients “stable or improved” throughout test period
Subscribe now